New treatments for preeclampsia move closer to patients

Emily Chaddock’s experience highlights the danger of severe preeclampsia, a pregnancy complication that can threaten both mother and baby. At 27 weeks she developed the condition, leading to a rapid decline in health and a frightening hospital stay.

Researchers say several drug candidates aimed at preventing or treating preeclampsia are now advancing through early clinical testing. These programs are focused on improving blood vessel function and reducing the risk of organ damage that characterizes the disease.

If the trials succeed, the new therapies could give obstetricians more tools to protect high‑risk pregnancies, offering hope to families like the Chaddocks and creating a new market for biotech firms working in maternal health.